Erika P. Hamilton, MD
The treatment landscape for patients with HER2-positive breast cancer continues to evolve, with a potential new FDA approval on the horizon, explains Erika P. Hamilton, MD.
on Breast Cancer, Hamilton, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discussed the current treatment landscape for patients with HER2-positive breast cancer.
OncLive: Can you provide an overview of your presentation?
I provided updates in HER2-positive breast cancer, particularly in the early-stage setting, as well as the neoadjuvant and adjuvant data. We’ve recently received word that pertuzumab is on fast track for approval for consideration in early 2018 for adjuvant therapy.
... to read the full story